IRadimed expects Q3 revenue of $23.0 million to $24.5 million.
The company sees Q3 GAAP diluted EPS of $0.49 to $0.54 and non-GAAP EPS of $0.54 to $0.59.
IRadimed reaffirmed 2026 revenue guidance of $91.0 million to $96.0 million and GAAP EPS of $1.90 to $2.05.
Result drivers
New product launch - The company said Q2 marked the start of the 3870 MR IV pump launch and transition from the older 3860 model, with initial shipments meeting plan.
Record monitor bookings - The company said domestic monitor unit bookings set a record in Q2.
Gross margin pressure - The company said gross margin declined due to expected startup challenges with the new 3870 pump ramp, but expects improvement as volumes increase.
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or , no and no or .
IRMD•
